Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval symbols : Amrx save search
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 6.67%
H: 6.08%
C: 5.03%
fda opioid approval treatment for spray
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 0.0%
H: 0.33%
C: -2.64%
fda approval
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
Published: 2023-09-06 (Crawled : 22:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 3.14%
H: 0.0%
C: -6.09%
fda approval injection
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
Published: 2023-09-06 (Crawled : 14:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 3.14%
H: 0.0%
C: -6.09%
fda approval
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
Published: 2023-07-03 (Crawled : 22:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: -2.26%
H: 0.66%
C: 0.66%
xyrem fda authorized approval
Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
Published: 2023-06-14 (Crawled : 22:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 2.33%
H: 4.17%
C: 1.14%
rtu fda approval
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval
Published: 2022-12-20 (Crawled : 17:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: -0.46%
H: 0.47%
C: -2.33%
approval injection
Amneal Receives FDA Approval for Leuprolide Acetate Injection
Published: 2022-11-02 (Crawled : 12:20) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 0.86%
H: 0.0%
C: -10.21%
fda approval injection
Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA® (pegfilgrastim-pbbk)
Published: 2022-05-31 (Crawled : 21:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: -0.87%
H: 0.0%
C: 0.0%
fylnetra biosimilar approval
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)
Published: 2022-05-27 (Crawled : 11:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 1.88%
H: 0.71%
C: -1.7%
biosimilar approval
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
Published: 2022-04-13 (Crawled : 21:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: -0.7%
H: 6.46%
C: 1.88%
alymsys approval
Kashiv Biosciences Receives Approval for Its First Biosimilar RELEUKOTM (filgrastim-ayow)
Published: 2022-03-02 (Crawled : 19:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: -7.42%
H: 1.89%
C: -5.19%
approval bioscience hiv biosimilar
Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)
Published: 2022-03-01 (Crawled : 22:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
approval biosimilar
Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
Published: 2021-11-19 (Crawled : 14:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: -1.31%
H: 4.08%
C: 1.99%
approval ophthalmic emulsion
Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA
Published: 2021-10-27 (Crawled : 14:15) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: -2.91%
fda approval
Amneal Receives Approval for Generic TobraDex®
Published: 2021-07-19 (Crawled : 21:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: -2.09%
H: 2.37%
C: 2.37%
approval
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.